Anthracyclines

• 

  Subject Areas on Research

  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. 
  • A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. 
  • African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. 
  • Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. 
  • Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. 
  • Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. 
  • CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. 
  • Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. 
  • Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. 
  • Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. 
  • Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. 
  • Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. 
  • Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors. 
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. 
  • Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. 
  • Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. 
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. 
  • Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. 
  • Leveraging Clinical Informatics Tools to Extract Cumulative Anthracycline Exposure, Measure Cardiovascular Outcomes, and Assess Guideline Adherence for Children With Cancer. 
  • Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. 
  • Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. 
  • Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. 
  • Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. 
  • Natural product glycosyltransferases: properties and applications. 
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. 
  • Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer. 
  • Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. 
  • Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. 
  • Prevention of chemotherapy and radiation toxicity with glutamine. 
  • Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma. 
  • Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection? 
  • Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition. 
  • Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. 
  • Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. 
  • Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. 
  • Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity.